BioMarin Pharmaceuticals BMRN Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's shares (diluted)?
- BioMarin Pharmaceuticals (BMRN) reported shares (diluted) of 197.7M in Q1 2026.
- How has BioMarin Pharmaceuticals's shares (diluted) changed year-over-year?
- BioMarin Pharmaceuticals's shares (diluted) increased by 0.6% year-over-year, from 196.5M to 197.7M.
- What is the long-term trend for BioMarin Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's shares (diluted) has grown at a 1.6% compound annual growth rate (CAGR), from 735.9M to 783M.
- What does shares (diluted) mean?
- The average number of shares outstanding including all potential shares from options and convertible debt.
- How do you interpret shares (diluted)?
- A higher number relative to basic shares indicates a larger potential for dilution from employee compensation or convertible debt.
- How does shares (diluted) compare across companies?
- Essential for comparing the potential dilution impact of equity-based compensation plans across peer companies.